-
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
-
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
-
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
-
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: New share capital registered
